125I粒子联合AZD1152对三阴性乳腺癌细胞增殖和凋亡的影响

doi:10.3969/j.issn.1004-616x.2022.04.009

摘要/Abstract

摘要： 目的：研究¹²⁵I粒子联合Aurora激酶抑制剂AZD1152对三阴性乳腺癌(TNBC)细胞MDA-MB-231增殖和凋亡的影响。方法：试验设对照组(常规培养)、¹²⁵I粒子照射组(照射组)、1 μmol/L AZD1152作用MDA-MB-231细胞48 h组(抑制组)、¹²⁵I粒子照射与1 μmol/L AZD1152联合作用MDA-MB-231细胞48 h组(联合组)。采用免疫荧光检测细胞多核形成；四甲基噻唑蓝(MTT)法检测细胞增殖抑制率；CCK-8检测细胞活力；流式细胞术PI单染检测细胞周期；流式细胞术Annexin V/PI双染观察各组细胞凋亡情况；Western blot检测各组细胞中Cyclin B1、组蛋白H3的表达及其磷酸化水平的改变，以及凋亡相关蛋白Bcl-2、Bax、PARP表达的变化。结果：免疫荧光检测发现1 μmol/L AZD1152作用MDA-MB-231细胞48 h时可见到多核细胞形成；MTT试验结果显示对照组、照射组、抑制组和联合组的细胞增殖抑制率分别为(0.61±0.32)%、(17.62±1.41)%、(29.67±0.41)%、(53.17±1.26)%；CCK-8检测显示细胞存活率分别为(94.88±0.22)%、(59.21±0.14)%、(42.05±0.17)%、(32.12±0.36)%；细胞周期检测发现G2/M期占比分别为(18.99±0.15)%、(38.05±0.23)%、(49.80±0.32)%、(75.52±0.45)%，与对照组比较差异均具有统计学意义(P<0.05)。照射组、抑制组和联合组的细胞凋亡率分别为(17.48±0.24)%、(29.23±0.02)%、(63.11±0.27)%，均较对照组(0.31±0.03)%升高(P<0.05)。流式细胞术发现抑制组细胞出现多核及多倍体细胞，易形成非整倍体。Western blot检测结果显示联合组较其他3组，抗凋亡蛋白Bcl-2、组蛋白H3的磷酸化和Cyclin B1蛋白表达减少(P<0.05)，而促凋亡蛋白Bax和PARP蛋白剪切明显增加(P<0.05)。结论：¹²⁵I粒子对AZD1152有增敏作用，¹²⁵I联合AZD1152可显著抑制MDA-MB-231细胞组蛋白H3磷酸化及Cyclin B1水平，从而抑制细胞增殖，诱导细胞凋亡。

关键词: 乳腺癌, ¹²⁵I粒子, Aurora激酶, 细胞增殖, 凋亡

Abstract: OBJECTIVE: To study effects of AZD1152 combined with ¹²⁵I particles on proliferations and apoptoses of triple negative breast cancer cells MDA-MB-231. METHODS: Cultured cells were divided into several groups; control, ¹²⁵I particle irradiation, 1 μmol/L AZD1152 treatment with 48 h, treated with ¹²⁵I particle irradiation and 1 μmol/L AZD1152 treated with 48 h. Cell proliferation inhibitory rates were detected using the MTT and cell viability using the CCK-8 assays. Cell ploidies,cell cycles and apoptoses were detected using flow cytometry with cells separately stained by propidium iodide (PI) and by Annexin V/PI double-staining. Expressions of apoptosis-related proteins (Bcl-XL, Bcl-2 and PARP), CyclinB1 and Phosphorylation levels of Histone H3 were analyzed using Western blotting. RESULTS: After treatments for 48 h, cell proliferation inhibitory rates were (0.61±0.32)%,(17.62±1.41)%,(29.67±0.41)%,(53.17±1.26)%,respectively. Cell viability rates were (94.88±0.22)%,(59.21±0.14)%,(42.05±0.17)% (32.12±0.36)%,respectively. The proportions of G2/M phase were (18.99±0.15)%,(38.05±0.23)%,(49.80±0.32)%,(75.52±0.45)%,respectively. The apoptosis rates of MDA-MB-231 cells were (17.48±0.24)%,(29.23±0.02)%,(63.11±0.27)%,with significantly differences in the different groups (P<0.05). Compared with (0.31 ±0.03)% in the control group, the observed increases were significant (P<0.05). Immunofluorescence and flow cytometry analyses showed that multinucleated and polyploid cells appeared in the 1μmol/L AZD1152 group in 48 hours,which were easy to form aneuploid cells. Compared with the irradiated,inhibitor and control groups,the combined irradiation with 1 μmol/L AZD1152 for 48 h effectively down-regulated the expressions of Bcl-2,p-Histone H3,CyclinB1 and promoted Bax and dissection of PARP (P<0.05). CONCLUSION: The combination of ¹²⁵I particles and AZD1152 treatments efficiently inhibited proliferation and promoted apoptosis in breast cancer cell line MDA-MB-231.

Key words: breast neoplasms, ¹²⁵I particles, aurora kinase, cell proliferation, apoptosis

中图分类号:

R737.9

张月, 王耀一, 武雪亮, 张志生, 杨修明, 姜洋, 乔志飞, 梁晚平, 薛军. ¹²⁵I粒子联合AZD1152对三阴性乳腺癌细胞增殖和凋亡的影响[J]. 癌变·畸变·突变, 2022, 34(4): 295-299,306.

ZHANG Yue, WANG Yaoyi, WU Xueliang, ZHANG Zhisheng, YANG Xiuming, JIANG Yang, QIAO Zhifei, LIANG Wanping, XUE Jun. The combination of ¹²⁵I particles and AZD1152 efficiently inhibited proliferation and promoted apoptosis of a triple negative breast cancer cell line[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 295-299,306.

参考文献

[1] ZEKRI A, MESBAHI Y, BOUSTANIPOUR E, et al.The potential contribution of microRNAs in anti-cancer effects of aurora kinase inhibitor (AZD1152-HQPA)[J].J Mol Neurosci, 2018, 65(4):444-455.
[2] YIN L, DUAN J J, BIAN X W, et al.Triple-negative breast cancer molecular subtyping and treatment progress[J].Breast Cancer Res, 2020, 22(1):61.
[3] HE J, QI Z H, ZHANG X F, et al.Aurora kinase B inhibitor barasertib (AZD1152) inhibits glucose metabolism in gastric cancer cells[J].Anticancer Drugs, 2019, 30(1):19-26.
[4] YANG D Y, LIN Y P, XUE C, et al.CT-guided percutaneous implantation of ¹²⁵I particles in treatment of early lung cancer[J].J Thorac Dis, 2020, 12(10):5996-6009.
[5] BARNABA N, LAROCQUE J R.Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma[J].Cell Cycle, 2021, 20(11):1041-1051.
[6] ZHANG Q Z, LI G L, SHANG J B, et al.Clinical study of a ¹²⁵I particle-integrated esophageal covered stent and hyperbaric oxygen in the treatment of advanced esophageal cancer[J].Rev Esp Enferm Dig, 2021, 113(8):576-579.
[7] 吴育,曹刚,石美琴,等.基于分子对接虚拟技术及Western blotting实验考察苍耳亭对肝癌上皮间质转化作用靶点的影响[J].药物评价研究, 2017, 40(11):1535-1540.
[8] WANG Y Q, ZHU L H, LIN X, et al.Therapeutic effect of CT-guided ¹²⁵I seed implantation on advanced lung cancer and pulmonary metastatic carcinoma[J].Chin J Lung Cancer, 2020, 23(6):424-428.
[9] WANG Y, KANG P, HE W, et al.MR-guided ¹²⁵I seed implantation treatment for maxillofacial malignant tumor[J].J Appl Clin Med Phys, 2021, 22(1):92-99.
[10] CAO J Q, WANG Z X, CAI H Z, et al.Effect of PTCD-based biliary stent placement combined with ¹²⁵I particle intracavitary irradiation in treating pancreatic head cancer[J].J BUON, 2020, 25(2):1056-1062.
[11] LI F N, ZHANG Q Y, LI O, et al.ESRRA promotes gastric cancer development by regulating the CDC25C/CDK1/CyclinB1 pathway via DSN₁[J].Int J Biol Sci, 2021, 17(8):1909-1924.
[12] RAY-GALLET D, ALMOUZNI G.The histone H3 family and its deposition pathways[J].Adv Exp Med Biol, 2021, 1283:17-42.
[13] CHEN F, ZHU X Q, ZHENG J, et al.RHAMM regulates the growth and migration of lung adenocarcinoma A549 cell line by regulating Cdc2/CyclinB1 and MMP9 genes Running title:RHAMM regulates the growth of lung adenocarcinoma cells[J].Math Biosci Eng, 2020, 17(3):2150-2163.
[14] LV S, NING H B, LI Y X, et al.Inhibition of cyclinB1 suppressed the proliferation, invasion, and epithelial mesenchymal transition of hepatocellular carcinoma cells and enhanced the sensitivity to TRAIL-induced apoptosis[J].Onco Targets Ther, 2020, 13:1119-1128.
[15] LI H Y, LIANG D S, HU N M, et al.Helicobacter pylori inhibited cell proliferation in human periodontal ligament fibroblasts through the Cdc25C/CDK1/cyclinB1 signaling cascade[J].J Periodontal Implant Sci, 2019, 49(3):138-147.
[16] NAN J, ZHANG S R, ZHAN P, et al.Discovery of novel GMPS inhibitors of Candidatus Liberibacter asiaticus by structure based design and enzyme kinetic[J].Biology, 2021, 10(7):594.

¹²⁵I粒子联合AZD1152对三阴性乳腺癌细胞增殖和凋亡的影响

The combination of ¹²⁵I particles and AZD1152 efficiently inhibited proliferation and promoted apoptosis of a triple negative breast cancer cell line

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王绪娟, 罗永鑫, 李陈强, 王汝晋, 郑婷婷. 术前检查指标dNLR、SII、CRP/ALB对乳腺癌复发转移的预测价值[J]. 癌变·畸变·突变, 2022, 34(4): 284-288,323.
[2]	赵晨茜, 徐安琦, 艾多, 孔德钦, 张晓迪, 李文丽, 海春旭, 刘江正. 线粒体靶向抗氧化剂Mito-TEMPO对氮芥诱导BEAS-2B细胞损伤的影响[J]. 癌变·畸变·突变, 2022, 34(3): 161-168.
[3]	范晓杰, 李清靖, 谷丽娜, 桑梅香, 单保恩. 黑色素瘤相关抗原A基因在乳腺癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(3): 184-191.
[4]	张琪, 刘宇峻, 庄喜兵, 乔田奎. 附子提取物对肺癌A549细胞增殖抑制及放射增敏作用的研究[J]. 癌变·畸变·突变, 2022, 34(3): 227-232.
[5]	辛雨濛, 梁桓熙, 孙震晓. 甘草干姜汤抗小鼠乳腺癌实验研究[J]. 癌变·畸变·突变, 2022, 34(2): 88-92.
[6]	王蕊, 刘颖, 吴娟, 纪晓坤, 马阳, 郭晓, 杜芸. 胸腔积液肺腺癌细胞中CXCR4、Ki67、MDM2、N-cadherin的表达及其与EGFR突变状态的关系[J]. 癌变·畸变·突变, 2022, 34(2): 114-118.
[7]	郭晓娟, 王金西, 牛广旭, 田云霄. EGFR与HER-2在不同分子类型乳腺癌中的表达及其相关性分析[J]. 癌变·畸变·突变, 2022, 34(2): 119-123,148.
[8]	辛雨濛, 梁桓熙, 余悦华, 孙震晓. 基于网络药理学和分子对接法预测甘草干姜汤抗乳腺癌的主要活性成分及作用机制[J]. 癌变·畸变·突变, 2022, 34(1): 7-13.
[9]	赵岩, 孙震晓. 二甲双胍抑制人MDA-MB-231细胞增殖及迁移的体外实验研究[J]. 癌变·畸变·突变, 2022, 34(1): 35-39.
[10]	方煜彤, 张群琛, 洪超群, 陈春发, 陈炯玉, 张任栋, 吴俊东. 乳腺癌中miR-221、miR-222表达水平对GATA3和FOXA1蛋白的影响及其作用机制[J]. 癌变·畸变·突变, 2021, 33(6): 435-441,460.
[11]	李柏茹, 秦双建, 关岚, 李闰冰, 蔡颖, 蒲桔宁, 曾明, 肖芳, 徐新云. PM_2.5对HK-2细胞氧化损伤和凋亡的影响[J]. 癌变·畸变·突变, 2021, 33(5): 360-364.
[12]	张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.
[13]	黄晓华, 牛永东, 石刚刚. 核受体FXR激活对宫颈癌CaSki细胞增殖的抑制效应及其作用机制[J]. 癌变·畸变·突变, 2021, 33(4): 302-306.
[14]	王熙凯, 孟庆贺, 高燕鲁. miR-223-3p通过调控ECT2诱导非小细胞肺癌细胞凋亡的实验研究[J]. 癌变·畸变·突变, 2021, 33(3): 187-192.
[15]	程斌, 王新宇, 孙钰, 张家泰, 董淑英. 二甲双胍对DEHP和DBP诱导的MCF-7细胞增殖和迁移的抑制作用[J]. 癌变·畸变·突变, 2021, 33(3): 197-202.